GLP-1 Pipeline Update: February 2026 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Principal Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Development Director Senior, Pipeline DISCLAIMER The drug pipeline is fluid
Free Radic Biol Med 95:2742 Crum A (2011) Nutritional or therapeutic compositions and methods to increase bodily glutathione levels
Because peptides are naturally occurring and highly specific in their action, they carry minimal risk and are generally well-tolerated, with little to no side effects
Understanding these potential mechanisms helps patients and healthcare professionals distinguish between expected treatment effects and symptoms requiring urgent medical evaluation
combined with injections of tirzepatide, a drug used increasingly for weight loss
Retrieved from Centers for Disease Control and Prevention (CDC)